



UBS Virtual Global Healthcare Conference

May 19, 2020

Forward-Look Statements

This presentation contains statements that are not historical and that are based on our beliefs and assumptions and on information currently available to us. These statements constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from our expectations.


Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the current and future impacts of COVID-19 on Veracyte's business, actions Veracyte has taken, or will take, in response to COVID-19, potential timing for a recovery of Veracyte's business, the catalysts to drive momentum through 2021 and Veracyte's long-term outlook. Forward-looking statements are neither historical facts nor assurances of future performance, but are based only on our current beliefs, expectations and assumptions. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: the impact of COVID-19 on Veracyte's business and operating results, specifically, and the healthcare system and economy more generally, Veracyte's ability to achieve and maintain Medicare coverage for its tests; the benefits of Veracyte's tests and the applicability of clinical results to actual outcomes; the laws and regulations applicable to Veracyte's business, including potential regulation by the Food and Drug Administration or other regulatory bodies; Veracyte's ability to successfully achieve and maintain adoption of and reimbursement for its products; the amount by which use of Veracyte's products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in Veracyte's filings with the Securities and Exchange Commission, including the risks set forth in its quarterly report on Form 10-Q for the quarter ended March 31, 2020. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new info

Veracyte, Afirma, Percepta, Envisia, Prosigna, Lymphmark, Know by Design, the Veracyte logo, the Percepta logo, the Envisia logo and Afirma logo are trademarks of Veracyte, Inc. This presentation also contains trademarks and trade names that are the property of their respective owners.

[®] Veracyte, Inc. All rights reserved. May 2020




We are a global genomic diagnostics company transforming care throughout the patient journey. Founded with a mission to improve diagnostic accuracy




® Veracyte, Inc. All rights reserved. May 2020 CONFIDENTIAL

WHERE WE ARE TODAY


Answering clinical questions in more indications throughout the patient journey and forging valuable partnerships



Strong revenue growth driven by expanding sources



Strong Q1 2020 Revenue Growth



PLATFORM FOR EXPANSION


Exclusive global diagnostics rights to best-in-class system

nCounter FLEX Analysis System

- Simultaneous multiplex testing of up to 800 RNA, DNA and protein targets
- Elegantly simple, kit-enabled platform
- >80% reduction in hands-on time versus sequencing
- Presence in 22 countries
- Hundreds of installed systems




WHERE WE ARE GOING (5-10 Years) Global market, menu and margin expansion



® Veracyte, Inc. All rights reserved. May 2020 CONFIDENTIAL

WHERE WE ARE GOING (5-10 Years)

Attractive solution for diagnostic partners



® Veracyte, Inc. All rights reserved. May 2020 CONFIDENTIAL

Our foundational strategy drives our business

Relevant Questions

Integrated into current care pathway to change practice and reduce surgeries

Scientific Rigor

Build robust scientific and clinical evidence; inform guidelines

Value Creation

Clinical utility and economic value that change the standard of care


Successful Reimbursement

S

Extensive coverage policies and contracted relationships pave way for additional tests


11

Our science and technology engine powers growth




The Clinical Problem:

Patients lack actionable results throughout the care continuum




Our products provide clinical answers that improve patient care



ANSWERS that inform patient treatment decisions

THYROID CANCER


Improving patient outcomes in thyroid cancer




¹ Company estimates

LUNG CANCER

Improving the efficiency of lung cancer diagnosis



¹ Medicare Utilization and Physician Payment Public Use File (2016); Company research (2019) ² Silvestri et al, NEJM 2015 New risk assessment & diagnostic approach to improve standard of care




Meeting, Oct. 2019.

® Veracyte, Inc. All rights reserved. May 2020 CONFIDENTIAL


Preliminary Results

Accelerating diagnosis to get patients life-extending treatment faster



¹Company estimates ²Raghu et al, The Lancet Resp Med., 2019 **BREAST CANCER**

Inform next steps for patients with early-stage breast cancer



March to standard of care

Clinical Utility

Endocrine Practice, 2018

Analytical Verification

Thyorid, 2019

Thyorid, 2019

JCEM. 2013

Thyroid 2012

Frontiers, 2019

JCFM 2012

LAUNCHED IN 2011

Afirma GENOMIC SEQUENCING CLASSIFIEI

Published Evidence

Clinical Validation Frontiers, 2019 Cancer Cvto. 2019 JAMA Surg. 2018 JCEM 2010 NEJM 2012

Cost-Effectiveness and Quality of Life **JCEM 2011** Thyroid 2012

♥aetna

Guidelines

National Comprehensive Cancer Network (NCCN) Published 2013. Updated 2014 American Thyroid Association (ATA) Preliminary Guidelines 2014 UpToDate

Evidence-Based Clinical Decision Support Resource of Physicians Published 2013. Updated 2014 American Association of Clinical Endocrinology (AACE) Guideline Update in Process



PREMERA | Medicare HIGHMARK. Ciana Humana Horizon blue 🗑

LAUNCHED IN 2015

Percepta

Published Evidence

Clinical Validation The New England Journal of Medicine, 2015 BMC Medical Genomics. 2015

Clinical Utility

ATS, 2019 Chest, 2016 CHEST, 2018 BMC Pulmonary Medicine, 2016

Analytic Validity BMC Cancer, 2016

Cost Effectiveness Journal of Thoracic Oncology, 2017

Payer Coverage



LAUNCHED IN 2016

Envisia

Published Evidence

Clinical Validation Lancet Respiratory Medicine, 2019 Annals of American Thoracic Society, 2017 CHEST. 2018 BMC Pulmonary Medicine, 2018

Payer Coverage

Clinical Utility ATS 2019 Lancet Respiratory Medicine, 2019

Analytic Validity BMC Pulmonary Medicine, 2017





Published Evidence

Clinical Validation: J Clin Oncol. 2013 J Natl Cancer Inst. 2013 Ann Oncol., 2014 Clin Cancer Res., 2014 Ann Oncol., 2015 J Clin Oncol., 2015

J Clin Oncol., 2018

Clinical Utility: Curr Med Res Opin., 2015 Curr Med Res Opin., 2016 PloS One. 2017 Breast Cancer Res., 2018

Analytical Verification: BMC Cancer, 2014


Cost-Effectiveness: NICE Guidance, 2018

Guidelines: National Comprehensive Cancer Network (NCCN; 2015) **American Society of Clinical Oncologists** (ASCO: 2017) St. Gallen (2017 update) European Society for Medical Oncology (ESMO; 2015) National Institute for Health and Care Excellence (NICE: 2018)


Payer Coverage



STRONG PIPELINE FOR GLOBAL EXPANSION



Greater than \$40B global market opportunity*



* Company estimates

** Opportunity in strategic markets

COVID-19 Pandemic Business-Recovery Framework

	Scenario 1 – "V"	Scenario 2 – "U"	Scenario 3 -		
Business at "normal" level	Q3/Q4 2020	Q1/Q2 2021	>Q2 2021		
Priorities	Maintenance plan	Cash preservation Flexibility	Business and P&L realignment		
Response	Temporary hiring freeze Reduce non-essential travel and spend Maintain R&D investments	Temporary furlough Hiring freeze Reduce spend Exec/board/vendor contributions Maintain R&D investments	Headcount RIF Reduced spend Pipeline delay		
Strategic business focus	 Virtual customer engagement Biopharma collaborations Near-term revenue Long-term growth Business diversity 	 Biopharma collaborations Near-term revenue Long-term growth Business diversity Strategic leverage in pipeline development 	Longer-term growth aligned to new customer interfaces Investments prioritized for growth		
Best-case business resumption	Accelerate re-adoption for revenue growth	Reinstate furloughed employees Core product re-acceleration	"New normal" in running business		

Attractive financial profile

\$

Strong Total Revenue Growth 31%

Full-year 2019 over 2018 actuals

\$

Attractive "Gross Margin"

61% testing services Increases with collaboration revenue^{*}

\$

\$

Selling and Marketing Leverage

Scale single-structure in U.S. Focused dedicated resource in EU Leverage institutional stakeholder relationships

R&D, Medical and Clinical Operations

Extensive whole RNA-transcriptome & biorepository Advancing pulmonology pipeline Menu expansion on nCounter supports international expansion

Solid Cash Position

Over \$153.1 Million at March 31, 2020

*For the quarter ended March 31, 2020

® Veracyte, Inc. All rights reserved. May 2020 CONFIDENTIAL

Catalysts to drive continued momentum through 2021

	Product & Testing Revenue	Collaboration Revenue	Evidence Development	Pipeline Advancement / Menu Expansion
2020	 TBD due to Covid-19 impact 	 Loxo/Lilly Thyroid Cancer Acerta Pharma / Astra Zeneca Lymphoma 	 Envisia publications/ abstracts/presentations Percepta publications/ abstracts/presentations Prosigna publications/ abstracts/presentations 	 Afirma XA enhancements Nasal swab data NOBLE trial initiation LymphMark advances
2021	 Guideline inclusion (pulmonology) Reimbursement Expansion (pulmonology) 	 Johnson & Johnson nasal swab lung cancer Loxo/Lilly Thyroid Cancer Acerta Pharma / Astra Zeneca Lymphoma 	 Nasal swab pivotal clinical validation Envisia nCounter data 	 Nasal Swab US Launch Envisia nCounter Launch Percepta Atlas Launch

Experienced team with track record of success



Bonnie Anderson Chairman and Chief Executive Officer



Keith Kennedy Chief Financial Officer and Chief Operating Officer

AC P B GE Capital



Giulia Kennedy, Ph.D. Chief Scientific Officer and Chief Medical Officer

CHIRON CHIROR MILLION COMPANY





John Hanna Chief Commercial Officer

<u>IBM</u> Humana.



Freddie Bowie, Ph.D. Vice President, Corporate and Business Development



® Veracyte, Inc. All rights reserved. May 2020 CONFIDENTIAL